351 related articles for article (PubMed ID: 25275135)
21. A New Class of Antiretroviral Enabling Innate Immunity by Protecting APOBEC3 from HIV Vif-Dependent Degradation.
Bennett RP; Salter JD; Smith HC
Trends Mol Med; 2018 May; 24(5):507-520. PubMed ID: 29609878
[TBL] [Abstract][Full Text] [Related]
22. Cellular requirements for bovine immunodeficiency virus Vif-mediated inactivation of bovine APOBEC3 proteins.
Zhang W; Wang H; Li Z; Liu X; Liu G; Harris RS; Yu XF
J Virol; 2014 Nov; 88(21):12528-40. PubMed ID: 25142583
[TBL] [Abstract][Full Text] [Related]
23. Core-binding factor subunit beta is not required for non-primate lentiviral Vif-mediated APOBEC3 degradation.
Ai Y; Zhu D; Wang C; Su C; Ma J; Ma J; Wang X
J Virol; 2014 Oct; 88(20):12112-22. PubMed ID: 25122780
[TBL] [Abstract][Full Text] [Related]
24. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
[TBL] [Abstract][Full Text] [Related]
25. A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif/CBFβ interaction.
Duan S; Wang S; Song Y; Gao N; Meng L; Gai Y; Zhang Y; Wang S; Wang C; Yu B; Wu J; Yu X
J Biol Chem; 2020 Oct; 295(43):14592-14605. PubMed ID: 32817167
[TBL] [Abstract][Full Text] [Related]
26. Functional and Structural Insights into a Vif/PPP2R5 Complex Elucidated Using Patient HIV-1 Isolates and Computational Modeling.
Salamango DJ; McCann JL; Demir Ö; Becker JT; Wang J; Lingappa JR; Temiz NA; Brown WL; Amaro RE; Harris RS
J Virol; 2020 Oct; 94(21):. PubMed ID: 32847850
[TBL] [Abstract][Full Text] [Related]
27. HIV-1 viral infectivity factor (Vif) alters processive single-stranded DNA scanning of the retroviral restriction factor APOBEC3G.
Feng Y; Love RP; Chelico L
J Biol Chem; 2013 Mar; 288(9):6083-94. PubMed ID: 23316055
[TBL] [Abstract][Full Text] [Related]
28. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding.
Mehle A; Wilson H; Zhang C; Brazier AJ; McPike M; Pery E; Gabuzda D
J Virol; 2007 Dec; 81(23):13235-41. PubMed ID: 17898068
[TBL] [Abstract][Full Text] [Related]
29. HIV-1 Vif N-terminal motif is required for recruitment of Cul5 to suppress APOBEC3.
Evans SL; Schön A; Gao Q; Han X; Zhou X; Freire E; Yu XF
Retrovirology; 2014 Jan; 11():4. PubMed ID: 24422669
[TBL] [Abstract][Full Text] [Related]
30. Evolutionarily conserved pressure for the existence of distinct G2/M cell cycle arrest and A3H inactivation functions in HIV-1 Vif.
Zhao K; Du J; Rui Y; Zheng W; Kang J; Hou J; Wang K; Zhang W; Simon VA; Yu XF
Cell Cycle; 2015; 14(6):838-47. PubMed ID: 25590520
[TBL] [Abstract][Full Text] [Related]
31. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity.
Zhen A; Wang T; Zhao K; Xiong Y; Yu XF
J Virol; 2010 Feb; 84(4):1902-11. PubMed ID: 19939923
[TBL] [Abstract][Full Text] [Related]
32. The Structural Interface between HIV-1 Vif and Human APOBEC3H.
Ooms M; Letko M; Simon V
J Virol; 2017 Mar; 91(5):. PubMed ID: 28031368
[TBL] [Abstract][Full Text] [Related]
33. APOBEC3G and APOBEC3F Act in Concert To Extinguish HIV-1 Replication.
Krisko JF; Begum N; Baker CE; Foster JL; Garcia JV
J Virol; 2016 May; 90(9):4681-4695. PubMed ID: 26912618
[TBL] [Abstract][Full Text] [Related]
34. Structural determinants of HIV-1 Vif susceptibility and DNA binding in APOBEC3F.
Siu KK; Sultana A; Azimi FC; Lee JE
Nat Commun; 2013; 4():2593. PubMed ID: 24185281
[TBL] [Abstract][Full Text] [Related]
35. Distinct domains within APOBEC3G and APOBEC3F interact with separate regions of human immunodeficiency virus type 1 Vif.
Russell RA; Smith J; Barr R; Bhattacharyya D; Pathak VK
J Virol; 2009 Feb; 83(4):1992-2003. PubMed ID: 19036809
[TBL] [Abstract][Full Text] [Related]
36. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
[TBL] [Abstract][Full Text] [Related]
37. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics.
Albin JS; Harris RS
Expert Rev Mol Med; 2010 Jan; 12():e4. PubMed ID: 20096141
[TBL] [Abstract][Full Text] [Related]
38. APOBEC3 multimerization correlates with HIV-1 packaging and restriction activity in living cells.
Li J; Chen Y; Li M; Carpenter MA; McDougle RM; Luengas EM; Macdonald PJ; Harris RS; Mueller JD
J Mol Biol; 2014 Mar; 426(6):1296-307. PubMed ID: 24361275
[TBL] [Abstract][Full Text] [Related]
39. HIV restriction by APOBEC3 in humanized mice.
Krisko JF; Martinez-Torres F; Foster JL; Garcia JV
PLoS Pathog; 2013 Mar; 9(3):e1003242. PubMed ID: 23555255
[TBL] [Abstract][Full Text] [Related]
40. Identification of a Conserved Interface of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Vifs with Cullin 5.
Gu Q; Zhang Z; Gertzen CGW; Häussinger D; Gohlke H; Münk C
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263270
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]